Companies exits & IPO
Optimer is focused on the research and development of anti-infective products to treat serious bacterial infections. Optimer’s core drug discovery
technologies are licensed from Scripps Research Institute and Memorial Sloan-Kettering Cancer Center. The company has a portfolio of pre-clinical and
clinical stage antibiotic compounds. Optimer’s lead product is an antibiotic being developed for the treatment of C. difficile-associated diarrhea (CDAD),
the leading cause of institutional enteric infections.
Optimer went public in 2007 (NASDAQ), later acquired by Cubist Pharmaceuticals, Inc.(CBST) in October 2013.
CircuLite, Inc. is a medical device company founded in November 2004 by Accelerated Technologies, Inc. (ATI) to develop a pocket circulatory assist device for the treatment of NYHA Class III and early Class IV heart failure patients.
CircuLite was acquired by HeartWare in December 2013.
GeminX specializes in the discovery and development of novel small-molecule cancer therapeutics based on the regulation of apoptosis, the body’s
natural ability to destroy injured or damaged cells.
GeminX Biotechnologies was acquired by Cephalon (TEVA) in March 2011.
U-Systems designs, develops, manufactures and markets innovative ultrasound systems and computer-aided detection (CAD) software for medical ultrasound.
U-Systems was acquired by GE Healthcare in November 2012.
Kadmus is a biopharmaceutical company that exploits endocannabinoid pathways to develop innovative therapeutics.
Kadmus was acquired by Organon(Merck & Co.)in June 2007.
Calypso Medical Technologies
Calypso Medical is a medical device company that develops innovative technology to target unmet medical needs in radiation therapy.
Calypso was acquired by Varian Medical Systems in September 2011.